0.01
+0.0001(+1.05%)
Currency In USD
Address
5 West 21st Street
San Diego, NY 10010
United States of America
Phone
917 622 5800
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
N/A
| Name | Title | Pay | Year Born |
| Mr. James M. Rolke | Chief Executive Officer & Director | 813,226 | 1969 |
| Mr. Chester Stanley Zygmont III | Chief Financial Officer & Corporate Secretary | 564,006 | 1980 |
| Ms. Carol Odle | Senior Director of Clinical Projects | 0 | N/A |
| Ms. Sandra Vedrick | Vice President of Human Resources & Investor Relations | 0 | N/A |
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.